Related Experiment Videos
[Dilated cardiomyopathy: recent advances and current treatment]
1Profesor Titular de Medicina. Centro Médico. Caracas. Venezuela. hacquetalla@true.net
Revista Espanola De Cardiologia
|September 29, 2000
Summary
Dilated cardiomyopathy (DC) causes heart muscle weakening and affects millions. New therapies, including beta-blockers, significantly reduce mortality in congestive heart failure (CHF) patients.
Area of Science:
- Cardiology
- Genetics
- Pathophysiology
Context:
- Dilated cardiomyopathy (DC) is characterized by ventricular dilatation and systolic dysfunction.
- It is a significant cause of cardiac morbidity, leading to congestive heart failure (CHF) and arrhythmias.
- Prevalence estimates indicate left ventricular systolic dysfunction in 2-3% and CHF in 1.5% of the general population.
Purpose:
- To review the current understanding of dilated cardiomyopathy's pathogenesis, treatment, and prognosis.
- To highlight the impact of recent therapeutic advancements on mortality rates.
- To discuss future directions in research, particularly in genetic mechanisms.
Summary:
- DC pathogenesis involves genetic factors, viral infections, immune responses, and myocardial apoptosis.
- Mortality in severe CHF, previously high (50% at 2 years), has been reduced by "triple" therapy (diuretics, digoxin, ACE inhibitors).
- Additional mortality reduction (35%) is achieved with beta-blockers and spironolactone, with beta-blockers also decreasing sudden death.
Impact:
- Improved management strategies have significantly decreased mortality associated with severe CHF.
- Beta-blockers are now a near-mandatory treatment for stable chronic CHF due to their survival benefits.
- Cardiac transplantation and defibrillator implantation offer improved survival for specific patient groups.
- Advances in understanding genetic mechanisms hold promise for future treatment innovations.